DNA methylation-associated MYBPHL expression in LPS-induced myocardial injury

Septic myocardial injury is a major complication of bacterial infection in children, and effective early biomarkers and therapeutic targets remain insufficiently defined. Studies have shown that Myosin-binding protein H-like (MYBPHL) plays a crucial role in the maintenance of normal cardiac function. This study aimed to explore the association between MYBPHL expression, DNA methylation-related enzymes, and myocardial injury caused by bacterial infection, and to investigate the potential protective role of MYBPHL in an in vitro model. This study combined a clinical cohort with in vitro experiments. (1) Serum samples were collected from 27 children with bacterial infection and 22 age- and sex-matched healthy controls. Levels of LPS, MYBPHL, DNMT1, DNMT3A, BNP, and cTn-I were measured by ELISA. Patient demographics, clinical severity indicators (C-reactive protein, white blood cell count), and septic myocardial injury markers were recorded. (2) Mouse cardiomyocyte (MCM) cells were treated with lipopolysaccharide (LPS, 10 µg/mL, 24 h) to establish an in vitro model of LPS-induced myocardial injury. Expression of DNMT3A, TET1, and MYBPHL was manipulated by overexpression vectors or short hairpin RNA (shRNA) and assessed by RT-qPCR and Western blotting. Cell apoptosis was quantified by flow cytometry (Annexin V-FITC/PI staining) and cTn-I secretion by ELISA. (1) Compared with healthy controls, serum LPS (572.5 ± 41.44 vs. 536.4 ± 55.47 ng/mL), MYBPHL (1445 ± 105.8 vs. 1383 ± 107.1 ng/L), BNP (229.7 ± 19.9 vs. 219.3 ± 12.4 pg/mL), and cTn-I (398.7 ± 27.7 vs. 377.2 ± 33.18 ng/L) were significantly elevated in children with bacterial infection (all P < 0.05), while DNMT3A was significantly decreased (164.7 ± 11.36 vs. 173.8 ± 11.6 pg/mL; P < 0.01); DNMT1 showed no significant difference (915.1 ± 79.14 vs. 917.8 ± 78.16 pg/mL; P = 0.9045). These findings suggest a clinically relevant association between reduced DNMT3A, elevated MYBPHL, and septic myocardial injury. (2) In MCM cells, LPS treatment reduced DNMT3A and DNMT3B expression and increased TET1 expression, changes consistent with a net reduction in DNA methylation, and promoted cardiomyocyte apoptosis ( P < 0.05). Conversely, increasing DNA methylation potential via DNMT3A overexpression or TET1 knockdown suppressed MYBPHL expression and exacerbated LPS-induced myocardial injury. This injury was partially rescued by MYBPHL re-expression. MYBPHL may exert a compensatory, protective response against septic myocardial injury. Its expression is associated with and may be negatively regulated by the DNA methylation machinery, primarily through DNMT3A and TET1. MYBPHL represents a potential candidate biomarker and therapeutic target for septic myocardial injury in children. Future studies employing animal models and genome-wide bisulfite sequencing are warranted to confirm whether direct methylation of the MYBPHL promoter occurs and to extend these findings in vivo.

Authors

Institutions

Publication Details

Journal
BMC Medical Genomics
Published
2026-11-17
DOI
https://doi.org/10.1186/s12920-026-02495-3
Primary Topic
Sepsis Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA methylation-associated MYBPHL expression in LPS-induced myocardial injury

Airong Huang, 林楚君, 林苗苗, Hailun Cai et al.
2 links
BMC Medical Genomics
Sepsis Diagnosis and Treatment
article

DNA methylation-associated MYBPHL expression in LPS-induced myocardial injury

Airong Huang, 林楚君, 林苗苗, Hailun Cai, YangYang Wu, Lisha Ge, Weihao Yu, Shanhu Wang, Jingxiang Du
article en

Abstract

Septic myocardial injury is a major complication of bacterial infection in children, and effective early biomarkers and therapeutic targets remain insufficiently defined. Studies have shown that Myosin-binding protein H-like (MYBPHL) plays a crucial role in the maintenance of normal cardiac function. This study aimed to explore the association between MYBPHL expression, DNA methylation-related enzymes, and myocardial injury caused by bacterial infection, and to investigate the potential protective role of MYBPHL in an in vitro model. This study combined a clinical cohort with in vitro experiments. (1) Serum samples were collected from 27 children with bacterial infection and 22 age- and sex-matched healthy controls. Levels of LPS, MYBPHL, DNMT1, DNMT3A, BNP, and cTn-I were measured by ELISA. Patient demographics, clinical severity indicators (C-reactive protein, white blood cell count), and septic myocardial injury markers were recorded. (2) Mouse cardiomyocyte (MCM) cells were treated with lipopolysaccharide (LPS, 10 µg/mL, 24 h) to establish an in vitro model of LPS-induced myocardial injury. Expression of DNMT3A, TET1, and MYBPHL was manipulated by overexpression vectors or short hairpin RNA (shRNA) and assessed by RT-qPCR and Western blotting. Cell apoptosis was quantified by flow cytometry (Annexin V-FITC/PI staining) and cTn-I secretion by ELISA. (1) Compared with healthy controls, serum LPS (572.5 ± 41.44 vs. 536.4 ± 55.47 ng/mL), MYBPHL (1445 ± 105.8 vs. 1383 ± 107.1 ng/L), BNP (229.7 ± 19.9 vs. 219.3 ± 12.4 pg/mL), and cTn-I (398.7 ± 27.7 vs. 377.2 ± 33.18 ng/L) were significantly elevated in children with bacterial infection (all P < 0.05), while DNMT3A was significantly decreased (164.7 ± 11.36 vs. 173.8 ± 11.6 pg/mL; P < 0.01); DNMT1 showed no significant difference (915.1 ± 79.14 vs. 917.8 ± 78.16 pg/mL; P = 0.9045). These findings suggest a clinically relevant association between reduced DNMT3A, elevated MYBPHL, and septic myocardial injury. (2) In MCM cells, LPS treatment reduced DNMT3A and DNMT3B expression and increased TET1 expression, changes consistent with a net reduction in DNA methylation, and promoted cardiomyocyte apoptosis ( P < 0.05). Conversely, increasing DNA methylation potential via DNMT3A overexpression or TET1 knockdown suppressed MYBPHL expression and exacerbated LPS-induced myocardial injury. This injury was partially rescued by MYBPHL re-expression. MYBPHL may exert a compensatory, protective response against septic myocardial injury. Its expression is associated with and may be negatively regulated by the DNA methylation machinery, primarily through DNMT3A and TET1. MYBPHL represents a potential candidate biomarker and therapeutic target for septic myocardial injury in children. Future studies employing animal models and genome-wide bisulfite sequencing are warranted to confirm whether direct methylation of the MYBPHL promoter occurs and to extend these findings in vivo.

BMC Medical Genomics
Wenzhou Medical University (CN), Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
Wenzhou Municipal Science and Technology Bureau
Good health and well-being
Sepsis Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon